Homo‐ and Hetero‐dinuclear Arene‐Linked Osmium(II) and Ruthenium(II) Organometallics: Probing the Impact of Metal Variation on Reactivity and Biological Activity. Issue 50 (7th August 2020)
- Record Type:
- Journal Article
- Title:
- Homo‐ and Hetero‐dinuclear Arene‐Linked Osmium(II) and Ruthenium(II) Organometallics: Probing the Impact of Metal Variation on Reactivity and Biological Activity. Issue 50 (7th August 2020)
- Main Title:
- Homo‐ and Hetero‐dinuclear Arene‐Linked Osmium(II) and Ruthenium(II) Organometallics: Probing the Impact of Metal Variation on Reactivity and Biological Activity
- Authors:
- Wilson, Christopher S.
Prior, Timothy J.
Sandland, Jordon
Savoie, Huguette
Boyle, Ross W.
Murray, Benjamin S. - Abstract:
- Abstract: Dinuclear metallodrugs offer much potential in the development of novel anticancer chemotherapeutics as a result of the distinct interactions possible with bio‐macromolecular targets and the unique biological activity that can result. Herein, we describe the development of isostructural homo‐dinuclear Os II –Os II and hetero‐dinuclear Os II –Ru II organometallic complexes formed from linking the arene ligands of [M(η 6 ‐arene)(C2 O4 )(PTA)] units (M=Os/Ru; PTA=1, 3, 5‐triaza‐7‐phosphaadamantane). Using these complexes together with the known Ru II –Ru II analogue, a chromatin‐modifying agent, we probed the impact of varying the metal ions on the structure, reactivity and biological activity of these complexes. The complexes were structurally characterised by X‐ray diffraction experiments, their stability and reactivity were examined by using 1 H and 31 P NMR spectroscopy, and their biological activity was assessed, alongside that of mononuclear analogues, through MTT assays and cell‐cycle analysis (HT‐29 cell line). The results revealed high antiproliferative activity in each case, with cell‐cycle profiles of the dinuclear complexes found to be similar to that for untreated cells, and similar but distinct profiles for the mononuclear complexes. These results indicate these complexes impact on cell viability predominantly through a non‐DNA‐damaging mechanism of action. The new Os II –Os II and Os II –Ru II complexes reported here are further examples of a family ofAbstract: Dinuclear metallodrugs offer much potential in the development of novel anticancer chemotherapeutics as a result of the distinct interactions possible with bio‐macromolecular targets and the unique biological activity that can result. Herein, we describe the development of isostructural homo‐dinuclear Os II –Os II and hetero‐dinuclear Os II –Ru II organometallic complexes formed from linking the arene ligands of [M(η 6 ‐arene)(C2 O4 )(PTA)] units (M=Os/Ru; PTA=1, 3, 5‐triaza‐7‐phosphaadamantane). Using these complexes together with the known Ru II –Ru II analogue, a chromatin‐modifying agent, we probed the impact of varying the metal ions on the structure, reactivity and biological activity of these complexes. The complexes were structurally characterised by X‐ray diffraction experiments, their stability and reactivity were examined by using 1 H and 31 P NMR spectroscopy, and their biological activity was assessed, alongside that of mononuclear analogues, through MTT assays and cell‐cycle analysis (HT‐29 cell line). The results revealed high antiproliferative activity in each case, with cell‐cycle profiles of the dinuclear complexes found to be similar to that for untreated cells, and similar but distinct profiles for the mononuclear complexes. These results indicate these complexes impact on cell viability predominantly through a non‐DNA‐damaging mechanism of action. The new Os II –Os II and Os II –Ru II complexes reported here are further examples of a family of compounds operating via mechanisms of action atypical of the majority of metallodrugs, and which have potential as tools in chromatin research. Abstract : Dinuclear metallodrugs : A family of homo‐dinuclear and hetero‐dinuclear arene‐linked Os II ‐Os II and Os II ‐Ru II organometallic complexes has been developed, and a comparative study with the isostructural Ru II –Ru II analogue, a chromatin‐modifying agent, is described. … (more)
- Is Part Of:
- Chemistry. Volume 26:Issue 50(2020)
- Journal:
- Chemistry
- Issue:
- Volume 26:Issue 50(2020)
- Issue Display:
- Volume 26, Issue 50 (2020)
- Year:
- 2020
- Volume:
- 26
- Issue:
- 50
- Issue Sort Value:
- 2020-0026-0050-0000
- Page Start:
- 11593
- Page End:
- 11603
- Publication Date:
- 2020-08-07
- Subjects:
- bioinorganic -- bio-organometallic -- cancer -- dinuclear complexes -- metallodrugs
Chemistry -- Periodicals
540 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-3765 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/chem.202002052 ↗
- Languages:
- English
- ISSNs:
- 0947-6539
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3168.860500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22599.xml